stockrowArtivion, Inc.
AORT Healthcare Medical Devices
Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024.
- Revenue
- +9.17%
- EPS
- −214.3%
- Free cash flow
- −199.5%
- Total debt
- +68.2%
Quarter to September 2026, against a year earlier
Follow AORT
Alert me
Artivion, Inc. (AORT) EV/Sales
As of 6 November 2026, Artivion, Inc. (AORT) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from 1.4× (February 2016) to 6.6× (September 2018); the current reading is higher than 22% of that period. That is above the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.0× | 34.35% |
| FY2024 | 3.7× | 34.86% |
| FY2023 | 2.8× | 17.20% |
| FY2022 | 2.4× | (32.67%) |
| FY2021 | 3.5× | (21.05%) |
| FY2020 | 4.5× | 3.27% |
| FY2019 | 4.3× | (6.53%) |
| FY2018 | 4.6× | 7.44% |
| FY2017 | 4.3× | 25.17% |
| FY2016 | 3.4× | 92.23% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.0× | 1.39% |
| Jun 2026 | 2.9× | (30.20%) |
| Mar 2026 | 4.2× | (16.67%) |
| Dec 2025 | 5.0× | (0.82%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.2× |
| ENOV Enovis Corporation compare | 1.3× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.3× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| ATEC Alphatec Holdings, Inc. compare | 2.0× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.8× |
| AORT Artivion, Inc. | 3.2× |
| SIBN SiBone compare | 4.4× |
| IRMD iRadimed Corporation compare | 11.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)